Journal of Dermatological Treatment最新文献_第5页

Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019. 2017年至2019年美国医疗保险受益人中dupilumab的使用、成本和处方模式

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2127304

Michael J Murphy, Shayan Cheraghlou, William Damsky, Jeffrey M Cohen

{"title":"Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019.","authors":"Michael J Murphy, Shayan Cheraghlou, William Damsky, Jeffrey M Cohen","doi":"10.1080/09546634.2022.2127304","DOIUrl":"https://doi.org/10.1080/09546634.2022.2127304","url":null,"abstract":"Dupilumab is a monoclonal antibody that inhibits the action of interleukin-4 and interleukin-13. Since FDA approval in 2017, dupilumab has revolutionized the treatment of moderate-tosevere atopic dermatitis (AD) and has gained approval for additional indications. Few studies have examined geographic trends in its adoption in the Medicare population and none have described temporal trends (1). Characterizing such trends is important given that access to biologics and dermatologic care for AD are geographically variable, with rural areas often experiencing decreased access and utilization (2,3). Identifying temporal trends, therefore, may be useful in detecting widening disparities and considering interventions to improve access. Our study may also be helpful in understanding the impact of recently expanded dupilumab indications on prescription patterns. Prescribers, beneficiaries, and costs of dupilumab prescriptions were obtained from publicly available Centers for Medicare and Medicaid Services (CMS) Medicare Provider Utilization and Payment Data: Part D (4). Prescriber-level and geographic trends were analyzed for prescribers who submitted 10 claims annually. Counties were assigned a Rural-Urban Continuum Code (RUCC) based on the National Center for Health Statistics Urban-Rural Classification Scheme for Counties and categorized into metro (RUCC 1–3) or non-metro (RUCC 4–9). As of 2019, there were 7944 prescribers of dupilumab, representing more than a five-fold increase since 2017 (Table 1). The mean claims per prescriber nearly doubled, resulting in a nearly 10-fold increase in total dupilumab claims. Total drug cost increased proportionally to claims.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3214-3215"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10424448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review. 痤疮、特应性皮炎和牛皮癣临床试验中美国参与者的种族和民族多样性:一项全面的综述。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2114783

Anjana Sevagamoorthy, Patrick Sockler, Christine Akoh, Junko Takeshita

{"title":"Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review.","authors":"Anjana Sevagamoorthy, Patrick Sockler, Christine Akoh, Junko Takeshita","doi":"10.1080/09546634.2022.2114783","DOIUrl":"https://doi.org/10.1080/09546634.2022.2114783","url":null,"abstract":"An increasing body of literature describes underreporting of race and ethnicity, and overrepresentation of White individuals in clinical trials. We aimed to evaluate the racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis (AD), and psoriasis. We performed a comprehensive review of clinical trials for these common dermatologic diseases that were published between January 2014 and July 2019. Race and ethnicity reporting among all trials, and the racial and ethnic distribution of US participants were compared by skin disease, intervention type, and trial phase. In total, 103 articles representing 119 unique trials were evaluated. Race and ethnicity were reported in only 22.7% of trials. The proportion of White participants (77.5%) was higher than that of the US population (72.5%, p < .01); a finding largely driven by psoriasis trials (84.7% White). The proportions of non-White and Hispanic individuals in non-topical (21.0 and 16.3%, respectively) and Phase III (20.5 and 18.7%, respectively) trials were lower than those in topical (23.5 and 23.3%, respectively; p < .01) and Phase I/II trials (25.6 and 22.3%, respectively; p < .01). Race and ethnicity remain underreported in dermatologic clinical trials, and US trial participant diversity differs by skin disease, intervention type, and trial phase.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3086-3097"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10759061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline - a multivariable regression analysis from the German Psoriasis Registry PsoBest. 在现实世界的实践中，富马酸酯治疗斑块型银屑病的反应在很大程度上与基线时的患者特征无关——来自德国银屑病登记处PsoBest的多变量回归分析。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2115285

Kristian Reich, Ulrich Mrowietz, Christina Sorbe, Ralph von Kiedrowski, Sebastian Diemert, Lisa Schaeffer, Natalia Kirsten, Nesrine Ben-Anaya, Matthias Augustin

{"title":"Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline - a multivariable regression analysis from the German Psoriasis Registry PsoBest.","authors":"Kristian Reich, Ulrich Mrowietz, Christina Sorbe, Ralph von Kiedrowski, Sebastian Diemert, Lisa Schaeffer, Natalia Kirsten, Nesrine Ben-Anaya, Matthias Augustin","doi":"10.1080/09546634.2022.2115285","DOIUrl":"https://doi.org/10.1080/09546634.2022.2115285","url":null,"abstract":"Objectives: Fumaric acid esters (FAEs) are a well-established treatment option for long-term therapy of moderate to severe plaque psoriasis. This study examines effectiveness of FAEs for the treatment of plaque psoriasis in real-world practice at 12 months and if patient characteristics affect the odds of clinical response.Methods: A descriptive, multivariable logistic regression analysis was conducted in a cohort drawn from the German registry PsoBest. Baseline patient characteristics were assessed as potential treatment effect modifiers.Results: 444 patients (mean age 47.0 years, 39.0% female) were eligible for response analysis using nonresponder imputation at month 12. Of these, 39.6% achieved clinical response, i.e. Psoriasis Area and Severity Index (PASI) ≤ 3 or skin clearance. In logistic regression analysis (R2 = 0.114), only baseline PASI was a significant factor: patients with PASI < 10 had a 4 times higher odds (p ≤ .001, OR 4.088), patients with PASI of 10-20 a twofold higher odds of response (p ≤ .044, OR 1.961) compared to those with PASI > 20. Neither sex, age, body weight, disease duration, comorbidity nor pretreatment had an impact on the odds of response (p > .05).Conclusions: FAEs showed a favorable response at 12 months, largely independent of patient characteristics.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3170-3177"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10759062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis. 固定剂量联合钙化三醇和二丙酸倍他米松(Cal/BDP)乳膏与Cal/BDP泡沫治疗牛皮癣的间接比较。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2116924

Anthony Bewley, Erin Barker, Hannah Baker, Will Green, Brooke Avey, Aina Pi-Blanque, Jordi Galván, Paw Trebbien, Morten Praestegaard

{"title":"An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis.","authors":"Anthony Bewley, Erin Barker, Hannah Baker, Will Green, Brooke Avey, Aina Pi-Blanque, Jordi Galván, Paw Trebbien, Morten Praestegaard","doi":"10.1080/09546634.2022.2116924","DOIUrl":"https://doi.org/10.1080/09546634.2022.2116924","url":null,"abstract":"Objectives: To undertake a comparison of Cal/BDP cream versus foam for the treatment of plaque psoriasis, with cross-trial population differences accounted for.Materials and methods: An anchored matching-adjusted indirect comparison was undertaken, using individual patient data for Cal/BDP cream and published aggregated data for Cal/BDP foam. Altogether, 11 outcomes were analyzed, including PGA success, mPASI75, DLQI-related outcomes and treatment satisfaction across numerous domains. For each outcome an odds ratio or mean difference was calculated to represent the relative efficacy of Cal/BDP cream versus foam. Methods were guided by NICE Decision Support Unit recommendations.Results: After adjustment, baseline characteristics were balanced across treatment arms in each analysis. There were no statistically significant differences in PGA success, mPASI75 or DLQI outcomes between Cal/BDP cream and foam when they were compared after their recommended treatment durations (8 weeks for cream and 4 weeks for foam). For treatment satisfaction after 1 week of treatment, Cal/BDP cream was significantly superior to the Cal/BDP foam in all but one domain of the questionnaire.Conclusions: Cal/BDP cream and Cal/BDP foam have equivalent efficacy and HRQoL (measured in DLQI) outcomes when used for the topical treatment of plaque psoriasis at their recommended treatment durations. A comparison of treatment satisfaction assessments after 1 week of treatment demonstrated that patients find Cal/BDP cream to be more convenient than foam.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3191-3198"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10787410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Reasons why adults do not seek treatment for acne: a survey of university students and staff. 成年人不寻求痤疮治疗的原因:一项对大学生和工作人员的调查。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2116925

Evan Baird, Ivy Click, Rebecca Kotsonis, Lorin Bibb

{"title":"Reasons why adults do not seek treatment for acne: a survey of university students and staff.","authors":"Evan Baird, Ivy Click, Rebecca Kotsonis, Lorin Bibb","doi":"10.1080/09546634.2022.2116925","DOIUrl":"https://doi.org/10.1080/09546634.2022.2116925","url":null,"abstract":"Background: Acne can be a highly debilitating disease. There is a high prevalence in adults, yet treatment rates in this population are low.Objectives: An online survey was created to determine the main reasons why adults with acne do not seek treatment.Methods: University students and staff 20 years of age and older were emailed a link to an online survey that asked them if they have facial acne, if they see a provider for it, and how they self-treat their acne.Results: 1,136 complete surveys were returned. Top reasons for not seeing a provider include not being bothered enough to seek treatment (n = 418, 53.7%), believing that their acne will eventually resolve on its own (n = 351, 45.1%), concerned about costs of treatment (n = 274, 35.2%), and currently satisfied with over-the-counter (OTC) treatment (n = 261, 33.5%).Conclusion: Most adults with acne do not see providers because they are not bothered enough by it or are satisfied with OTC treatments. However, of the population that has acne and does not seek treatment, a significant portion (n = 234, 30.1%) indicated it was for a reason that could be classified as a treatment barrier.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3188-3190"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10410822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JAK inhibitors in lichen planus: a review of pathogenesis and treatments. 扁平苔藓中的JAK抑制剂:发病机制和治疗的综述。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2116926

Ali Motamed-Sanaye, Yasaman Fatemeh Khazaee, Motahareh Shokrgozar, Maryam Alishahi, Najmeh Ahramiyanpour, Maliheh Amani

引用次数: 10

Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis. JAK抑制剂治疗儿童斑秃的疗效和安全性:一项系统综述和荟萃分析。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2133956

Yi Chen, Huijun Zhu, Yuqing Shen, Yuqi Zhu, Jiayi Sun, Yeqin Dai, Xiuzu Song

{"title":"Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis.","authors":"Yi Chen, Huijun Zhu, Yuqing Shen, Yuqi Zhu, Jiayi Sun, Yeqin Dai, Xiuzu Song","doi":"10.1080/09546634.2022.2133956","DOIUrl":"https://doi.org/10.1080/09546634.2022.2133956","url":null,"abstract":"Background: Alopecia areata (AA) is a non-scarring hair loss mediated by T lymphocytes. Recently, a growing number of studies have shown that Janus kinase inhibitors are effective in the treatment of AA in children.Methods: A systematic review and meta-analysis were performed according to the PRISMA guidelines. Good response was defined as more than 50% decrease in Severity of Alopecia Tool (SALT) score or complete regrowth or more than 50% regrowth. Partial response was defined as 5-50% decrease in SALT score. Any response to treatment was defined as more than 5% in SALT score decrease.Results: There were 81.9% responders, 68.5% good responders, and 7.7% partial responders among the 10 included studies. The treatment duration was longer in good responders than in partial responders (p = .009). Oral route was linked to a better response to topical medication, with an odds ratio of 7.8 (95%CI 1.655-36.76). In terms of toxicity, reported adverse events included only mild symptoms. Liver transaminase elevation, upper respiratory tract infection, and eosinophilia were the most common adverse events.Conclusions: Janus kinase inhibitors demonstrated promise in the treatment of AA in children, with the most common side effects being minor and reversible.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3143-3149"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10777561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Side effect jiu-jitsu. 柔术的副作用。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2151863

Rithi Chandy, Katherine L Keith, Steven R Feldman

引用次数: 0

Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting. 在美国现实世界环境中，secukinumab对生物初始银屑病患者报告的结果的影响。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2116266

Bruce Strober, Dhaval Patil, Robert R McLean, Melissa Moore-Clingenpeel, Ning Guo, Eugenia Levi, Mark Lebwohl

{"title":"Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting.","authors":"Bruce Strober, Dhaval Patil, Robert R McLean, Melissa Moore-Clingenpeel, Ning Guo, Eugenia Levi, Mark Lebwohl","doi":"10.1080/09546634.2022.2116266","DOIUrl":"https://doi.org/10.1080/09546634.2022.2116266","url":null,"abstract":"Objective: To describe real-world baseline characteristics and patient-reported outcomes (PROs) at 6-month and 12-month follow-up visits among patients with psoriasis who initiated and maintained secukinumab, stratified by prior exposure to biologics.Methods: This real-world study included patients enrolled in the CorEvitas (formerly Corrona) Psoriasis Registry who initiated and maintained secukinumab through 6-month and/or 12-month follow-up. Demographics, clinical characteristics, and PROs were collected. PROs included Dermatology Life Quality Index (DLQI); itch, skin pain, fatigue, and EuroQol visual analog scales; and Work Productivity and Activity Impairment. Mean (SD) differences between baseline and follow-up visits were calculated for all outcomes.Results: Overall, 652 patients had a 6-month follow-up visit, 460 (70.6%) were biologic experienced and 192 (29.4%) were biologic naive. Biologic-experienced and biologic-naive patients reported mean (SD) improvements in all PROs measured at 6-month follow-up. Similar improvements were seen among patients with a 12-month follow-up visit (n = 390) and both 6-month and 12-month follow-up visits (n = 326).Conclusions: Biologic-experienced and biologic-naive patients with psoriasis who initiated and maintained secukinumab treatment reported improvements in PROs at 6-month and/or 12-month follow-up visits. These findings suggest that secukinumab is a potential biologic for psoriasis at any point along the patient treatment journey.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3178-3187"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10470249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Initial validation of a new device for facial skin analysis. 面部皮肤分析新设备的初步验证。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2127305

Madison K Cook, Margaret A Kaszycki, Irma Richardson, Sarah L Taylor, Steven R Feldman

{"title":"Initial validation of a new device for facial skin analysis.","authors":"Madison K Cook, Margaret A Kaszycki, Irma Richardson, Sarah L Taylor, Steven R Feldman","doi":"10.1080/09546634.2022.2127305","DOIUrl":"https://doi.org/10.1080/09546634.2022.2127305","url":null,"abstract":"The field of dermatology is met with many subjective analysis methods. Due to the relative nature of subjective analysis methods, objective analysis methods with greater accuracy and reliability were developed. Many of these devices are either inaccessible to patients without being a part of a clinical trial, bulky, or costly. However, with the advances in artificial intelligence and handheld devices, measurement methods have become simplified. The purpose of our study was to validate an objective skin analysis software available on a handheld device by comparing it to a board-certified dermatologist's assessment. Participants of various ages and skin types were analyzed with the facial analysis system on an iPad Pro. The same photographs were ranked by a physician based on 14 common skin characteristics. The facial analysis system and the physician's rankings had a good agreement rate of 69%. The greatest agreement rates were with the assessment of erythema (83.7%) and wrinkles (81.6%) and the lowest with oiliness (53.1%). The analysis system's high re-test reliability and good agreement rates with physician assessment support its potential use in the clinical setting.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3150-3153"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10411095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2